Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3.6 million volume in 2 hours. Looking Good
I will take a look.. Thanks
Looks like the 50 & 200 day SMA are @.04
Price $0.068
Day's Change 0.00679
Volume 846,300 (+13.16%)
Time 10:01
Price $0.064
Day's Change 0.0039 (6.51%)
Volume 396,973
Time 9:51
So, what exactly is SVF Stem Cell Therapy?
A “stem cell” is any cell within your body that can not only replicate (multiply) but also turn itself into different types of cell. SVF, or Stromal Vascular Fraction, is a combination of stem cells and other regenerative cells as well as growth factors and cytokines that aid in repair and differentiation. If your body needs cartilage to repair or strengthen a joint, a stem cell can become that. Muscle tissue breakdown? Stem cells can do that too. Unlike the controversy-ridden practice of “embryonic stem cells,” the adult stem cells we use in our treatments are ones that already reside in every individual. These stem cells are extracted using a painless, outpatient procedure and once isolated, can differentiate into connective tissue, blood vessels, bone, and nerve tissue. In their “stem” form, these cells have no purpose other than to wait for instructions to differentiate as needed. But when a wound needs healing, or inflammation reduced they leap into action. In fact, you will be surprised to learn how many different conditions and diseases can be treated using just one type of tissue, namely your unused adipose (fat) tissue. As it turns out, fat is loaded with these valuable regenerative entities found in the SVF- stem cells. Because the majority of patients in the United States have an adequate stem cell count, the stem cells recovered can be used right away without the need of culturing, which is the rule with the other types of stem cell. While making the procedure more convenient for the patient, this also ensures that the cells have no chance of rejection because the cells are purely the product of the patient’s own body.
CEO Blog: February 2018
Posted by U.S. Stem Cell, Inc
Dear Shareholders and Friends,
Thank you all so much for taking the time to learn more about our recent progress. In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.
A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.
We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily. Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.
We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases. We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.
The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice. Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.
USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential. We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients. We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.
Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases. As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace. We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time. We are confident that timing is now.
USRM technologies are now offered in six continents with interest from various countries throughout the world growing. We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles. These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them. We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.
The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain. Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population. Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells. Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy. Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.
Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform. “Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants. Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.
In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield. The webinar, which is entitled “Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance. Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine. He was successful at increasing both size and rate of performance. To listen to that webinar in its entirety click here.
Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology. We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.
Warmest regards,
Mike Tomas,
President and CEO
Today should be another exciting day. Lots of new posters showing up. Another positive sign
Tomorrow should be another exciting day.. GLTA
Closed at .0601.. A very positive day for USRM.
“There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt, assurances to patients based on unproven and, in some cases, dangerously dubious products… In such an environment a select few, often motivated by greed without regard to responsible patient care, are able to promote unproven, clearly illegal, and often expensive treatments that offer little hope, and, even worse, may pose significant risks to the health and safety of vulnerable patients.”
6.1 million volume. Like to see a late surge to take us to 10 million and a closing price of .065-.0685
Another big spike in volume, guess they're back from lunch..
Thank you
BIOHEART, INC. (BHRT) Last trade was Jan 8, 2016 3:56 PM EST. I read that article also and wondered what was going on. Did some digging, maybe just an error
On the other side of the coin. I'm up 93% on my investment. Go Higher..
Like it or not, your fate is in the hands of market makers since they essentially control the stock market. Your order placed to buy or sell a stock on the OTC Markets will usually pass through one of the more trusted sources like NITE, ATDF, ETRF, and ARCA. Seeing a level 2 screen which only has these on it is what’s referred to as a “Clean Level 2” – one with no dirty hands on it. Typically, these four are there to do what markets makers are supposed to do which is simply fill buy & sell orders without attempting to manipulate the behaviour pattern of a particular stock.
When I see these four market makers on a level 2 screen, usually I will investigate the orders that have recently gone through to see if they were sells or buys in an effort to gauge the psychology of those involved already with the stock. Since there is a high probability these trades are being done by traders and not the market makers until given some reason to see otherwise, it gives some clearer insight as to an expected direction/momentum for stock on a given day.
Pump It
Given what’s been said so far, don’t put it past these four to play games and try to manipulate a stock. One of the signs is when you see a particular one on the top of the bid and ask with a spread wide enough to provide for them to scalp some profits in between. Regardless, these four are much less harmless than when you start getting into the “B” and “V” groups that can take something like that sounds all good and yet every bid posted gets whacked as fast as every ask order gets hit.
Market Makers To Watch Out For:
Alternative Execution Group AEXG
Maxim Group LLC MAXM
Puma Capital, LLC PUMA ?
Vandham Securities Corp. VNDM ?
BTIG, LLC BTIG
Vfinance Investments, Inc VFIN ?
The Vertical Trading Group, LLC VERT ?
Buckman, Buckman & Reid, Inc. BKRT ?
BMA Securities BMAK ?
GMP Securities, LLC MITR
INTL FCSTONE FINANCIAL INC INTL
R. F. Lafferty & Co., Inc. LAFC
Ascendiant Capital Markets, LLC ASCM
Delaney Equity Group LLC DLNY
Wall Street Access WABR
Spartan Securities Group, Ltd. MICA
Biltmore International Corporation BMIC
Wilson-Davis & Co., Inc. WDCO
DINOSAUR FINANCIAL GROUP, L.L.C DINO
D.A. Davidson & Co. DADA
Keefe, Bruyette & Woods, Inc. KBWI
Tradition Asiel Securities Inc. TRAS
Raymond James & Associates, Inc. RAJA
MONROE FINANCIAL PARTNERS, INC. MONR
Fig Partners, LLC BNKS
T.R. Winston & Company, LLC TRWN
Stockcross Financial Services, Inc. STXG
Rafferty Capital Markets, LLC RAFF
Stifel, Nicolaus & Company, Incorporated STFL
Wedbush Securities Inc. WEDB
Glendale Securities, Inc. GLED
Alpine Securities Corporation ALPS
CRT Capital Group LLC CRTC
The list above is based on order of recent activity with AEXG being the most active in transactions and CRTC the least active. The “Three C’s”: Citadel Securities (CDEL), Canaccord Genuity (CSTI) and Cantor Fitzgerald (CANT) are almost always on a ticker together with the four more trusted sources mentioned above. While these “Three C’s” are rarely toxic diluters, they can be heavy short sellers at times, taking advantage of a good thing which is part of the game.
Of the highlighted ones listed towards the top of the table, what you will experience most always when trying to battle with them is that when these diluting market makers appear, they will usually show 10,000 shares for trade. Countless “Ask Slaps” at that 10,000 do nothing as the count remains 10,000 due to a very deep well of securities to sell. Others listed lower like WDCO, STXG and GLED are brokerage houses which will take share certificates and clear them for low level toxic diluters (those who cut a deal with a company to buy some shares on the cheap).
pumaOf all those listed, PUMA is one which can make you pull your hair out more often than not. A lot of times you will see PUMA on the high bid and rarely, if ever, on the ask. Then, there are times where you will see PUMA boxed in (on the high bid and the high ask) with a wide enough spread to “scalp” the in between as well as scare investors into selling to them on the bid.
What PUMA will be looking to accomplish is one of two things: either accumulating ahead of an anticipated public event, or a short covering before a possible move to the upside. Either way, this battle can last weeks and makes seeing them atop the bid/ask of a ticker one you will only want to enter into if it’s understood you could be there for awhile.
Contrary to popular opinion, market makers don’t really have a license to print money like many try to insinuate. They get their $1,000,000 fines every other year from the SEC for jumping bids although they are required to buy and sell at bid and ask prices. Despite having the ability to hedge by short selling and swap agreements (which come across the screen as T-Trades or show “avg.” after it), both of which many individual investors see as “market manipulation,” they create the market for the little or no trading volume stocks.
Right To Try laws give people with terminal illnesses the legal right to use investigational medications years before they might otherwise be available on the market. No one can guarantee that a particular treatment will be effective, but these laws return choice and control over treatment options to where it is most effective: with patients and their doctors.
USRM Seeing Explosive Increase in Demand for Stem Cell Therapy
8:00 am ET February 6, 2018 (PR Newswire) Print
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics -- a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.
https://mma.prnewswire.com/media/614091/US_Stem_Cell_Logo.jpg
As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, "The Healing Miracle: The Truth About Stem Cells," will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.
"Our phones are ringing off the hook," said Dr. Comella. "Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain. Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments," said Dr. Comella.
Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.
"We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further," said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. "We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product," said Tomas. "We believe this is an indicator of continued growth to come."
Dr. Comella, who has more than 20+ years' experience and is one of the world's leading stem cell scientists, can be seen in The Healing Miracle docuseries here. To view Dr. Comella's interview online, click the link and fill out the information, which will provide complimentary access.
To access Dr. Comella's live webinar this Friday, Feb. 9, at Noon EST, click here to register or join. Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company's website and its Facebook page (https://www.facebook.com/USStemCellInc/).
USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy -- to date, more than 700+ physicians worldwide -- and has engaged with more than 287 clinics. Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. She has also been instrumental in developing and bringing to market USRM's AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient's own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.13794 NW 4th Street, Suite 212Sunrise, Fl 33325Phone: 954.835.1500Email: usstemcell@us-stemcell.com
https://c212.net/c/img/favicon.png?sn=FL07184&sd=2018-02-06
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-seeing-explosive-increase-in-demand-for-stem-cell-therapy-300594102.html
SOURCE U.S. Stem Cell, Inc.
https://rt.prnewswire.com/rt.gif?NewsItemId=FL07184&Transmission_Id=201802060800PR_NEWS_USPR_____FL07184&DateId=20180206
Last 7 minutes, big spike in volume
The Company recorded a loss on change in derivative liabilities of $1,891,205 during the nine months ended September 30, 2017. The remaining outstanding derivative liability at September 30, 2017 is $-0-
Charts have a Screaming Buy Signal
Anticipation of positive earnings will bring the buyers to the table. GLTA
We hit .05
I can't find any mention of U.S. Stem Cell, Inc in this link http://time.com/4920259/fda-crackdown-stem-cell-clinics/
Nothing but garbage information.
On March 3, 2017, we entered into an asset sale and lease agreement (sale/leaseback transaction; “Asset Sale and Lease Agreement”), with GACP (General American Capital Partners) Stem Cell Bank LLC, a Florida limited liability company (“GACP) whereby we sold certain lab, medical and other equipment relating to the cell banking business for $400,000 and leased back the sold equipment over a three year term. The lease includes a base monthly rental payment of $20,000, due the first day of each calendar month. In addition, we are required to pay 2.3%, 22.5% and 31.6% of revenues collected on deposits arising from cell banking business for
years 1, 2 and 3, respectively. At the expiration of the lease, we are required to return all leased equipment and along with any maintenance records, logs, etc. in our possession to the lessor with no right of repurchase. In addition, GACP has contractually agreed to invest an additional Two and a half Million Dollars ($2,500,000) to open ten (10) stem cell clinics in the United States within 3 years--with a penalty provision to our benefit for shortfalls if less than 6 clinics are opened within 24 months.
On August 7, 2017, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. The principal outstanding balance of this note as of September 30, 2017 is $300,000.
According to Robin R. Young’s Stem Cell Summit Executive Summary-Analysis and Market Forecasts 2014-2024, the United States stem cell therapy market is estimated to grow from an estimated $237 million in 2013 to more than $5.7 billion in 2020.
With approved cell therapy products currently being sold in the United States and abroad, and an increasing number of Phase 2 and Phase 3 trials with cell therapies underway, we believe the “promise” of cell therapy is becoming clearer. We contend that cell therapies, if approved, should cut health care costs as they aim to facilitate functional restoration of damaged tissues and not just abate or moderate symptoms. Safe and efficacious cell therapies for chronic diseases could potentially capture an increasing portion of future healthcare spending in the United States, driven both by favorable demographics and meaningful pharmacoeconomic
benefit.
Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction
Kristin Comella, Michelle Parlo, Rosemary Daly, Vincent Depasquale, Eric Edgerton, Patrick Mallory, Roy Schmidt, Walter P. Drake
Abstract
Background: Stem cells from adipose tissue offer a novel therapy for patients with damaged tissue. Stromal vascular fraction (SVF) injected into patients may reduce inflammation, promote healing, and repair damaged/scarred tissue. SVF can be isolated from fat (adipose) tissue in an outpatient procedure. The SVF population includes mesenchymal stem cells (MSCs), pericytes, endothelial/progenitor cells, fibroblasts and growth factors where the adipocyte (fat cell) population has been removed. Here we describe the use of SVF in the clinic for degenerative diseases in orthopedics, neurological conditions and systemic conditions in 676 patients.
Methods: This study demonstrated the strong safety profile from a multi-center analysis of SVF injection in treating various diseases. Approximately 60 mL of fat tissue was removed from the abdomen or flanks using a local tumescent liposuction procedure. The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient. All subjects were monitored for adverse events.
Results: The procedure demonstrates exceptional patient safety, and the study underscores the safety of autologous stem cell therapy in general. Few adverse events were reported and were overwhelmingly of mild and transient nature, such as the expected soreness at the site of liposuction and occasional headache.
Conclusion: The three deaths reported were most likely not related to the treatment but instead to the underlying disease. Our study demonstrates a strong safety profile with low complication rates.
Many studies have been conducted to cultivate and utilize patients’ own adipose-derived stem cells for the treatment of various incurable diseases and for regenerative medicine that can prolong lifespan. Despite the significant achievements made thus far, the lack of confidence with regard to safety, particularly the concern about Tumorigenicity, has made researchers hesitant to actively apply cultured human autologous adipose-derived cells in clinical trials. Therefore, studies on the Tumorigenicity of cultured adipose-derived stem cells are very important for expanding the field of stem cell–utilizing regenerative medicine. It is also important to study their effect on tumor biomarker levels. Long-term follow-up studies of Tumorigenicity after multiple intravenous administrations of cultured human autologous adipose-derived stem cells have not been reported worldwide. Therefore, the authors have examined about 500 Koreans who were administered more than 1 billion cultured autologous adipose-derived stem cells multiple times from 2010 to 2013 at a medical institution in Japan. We then conducted the first retrospective research in the world on the changes in eight types of tumor biomarkers over three–six years. According to the results of our analysis, there were no significant changes in the observed tumor biomarkers, irrespective of gender and age. These results suggest that multiple administrations of autologous adipose-derived stem cells cultured in accordance with the authors’ method do not affect Tumorigenicity.
Keywords: Adipose-derived stem cells; Multiple intravenous infusion; Tumor biomarker test; Tumorigenicity
Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases.
I’ll wager that no doctor or clinic will be cancelling appointments anytime soon.
Volume: 1,118,261 (Below Average)
Today's volume of 1,118,261 shares is on pace to be lower than USRM's 10-day average volume of 2,159,543 shares.
Volume: 1,118,261 (Below Average)
Today's volume of 1,118,261 shares is on pace to be lower than USRM's 10-day average volume of 2,159,543 shares.
Volume is 331.600 shares traded in the first hour. We need a medium push to get through .0498
.0498 Hold on
Your link ( http://abcnews.go.com/Health/wireStory/us-health-agency-crack-risky-stem-cell-offerings-51200556) on your previous post has no mentioning of this company or backing your statements of this stock..
The volume has really picked up in the afternoon
Anticipation before the company’s earnings report will move this stock higher heading towards the end of the week.
Thank you